Valuation : Lineage Cell Therapeutics, Inc.

Market Cap 260M 224M 211M 192M 360M 24.79B 361M 2.5B 967M 12.63B 978M 957M 40.01B P/E 2026 *
-15.3x
P/E 2027 * -9.88x
Enterprise Value 260M 224M 211M 192M 360M 24.79B 361M 2.5B 967M 12.63B 978M 957M 40.01B EV / Sales 2026 *
17.1x
EV / Sales 2027 * 15.5x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
1 day-5.50%
1 week-7.21%
Current month-6.36%
1 month-6.36%
3 months-15.57%
6 months-41.81%
Current year-38.32%
1 week 1.03
Extreme 1.03
1.16
1 month 1.03
Extreme 1.03
1.18
Current year 1
Extreme 1
1.98
1 year 1
Extreme 1
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.71
10 years 0.37
Extreme 0.3651
4
Manager TitleAgeSince
Chief Executive Officer 54 2018-09-16
Director of Finance/CFO 50 2022-11-13
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 60 2009-06-30
Director/Board Member 68 2014-04-10
Chairman 60 2024-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 Free

Director

125,000 0.0501%
7/1/26
Broadwood Capital, Inc.
FreeCompany 125,000 0.0501%
7/1/26 Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
-5.50%-7.21%-18.90%-24.26% 260M
+0.78%-6.98%-2.73%+11.12% 46.38B
+0.17%-0.74%+407.28%+546.58% 44.51B
-0.86%-2.60%+35.51%+20.35% 42.3B
-0.14%-2.98%-0.04%+82.21% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-3.44%-2.43% - - 17.13B
-0.78%-1.13%+20.74%+116.26% 16.36B
+0.62%-2.86%+13.38%+31.71% 14.31B
-0.86%-4.60%+76.86%+39.36% 13.29B
Average -1.22%-3.32%+60.61%+96.18% 26.72B
Weighted average by Cap. -0.55%-3.04%+85.92%+132.93%

Financials

2026 *2027 *
Net sales 15.19M 13.07M 12.31M 11.22M 20.99M 1.45B 21.07M 146M 56.39M 737M 57.05M 55.81M 2.33B 16.83M 14.49M 13.64M 12.43M 23.25M 1.6B 23.35M 162M 62.48M 816M 63.21M 61.84M 2.59B
Net income -22.64M -19.48M -18.34M -16.71M -31.27M -2.15B -31.4M -217M -84.03M -1.1B -85.01M -83.17M -3.48B -34.44M -29.64M -27.9M -25.43M -47.57M -3.28B -47.76M -331M -128M -1.67B -129M -127M -5.29B
Net Debt - -
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
26-09-10 $1.015 -1.46% 126,387
26-09-09 $1.030 -5.50% 1,364,316
26-09-08 $1.090 +0.93% 1,312,122
26-09-04 $1.080 -1.82% 535,726
26-09-03 $1.100 -0.90% 917,013
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.030USD
Average target price
5.500USD
Spread / Average Target
+433.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LCTX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!